Recursion Pharmaceuticals Inc Clas (RXRX)
EBITDA
-$444.45M
TTM · Period ending: · USD
RXRX EBITDA
Latest reported-$444.45Mperiod ending
Latest reported-$444.45Mperiod ending
RXRX TTM EBITDA (-$81.21M → -$444.45M)
TTM EBITDA
High-resolution chart · PNG
RXRX ebitda history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | EBITDA (USD) |
|---|---|
| -444,446,000 | |
| -479,484,000 | |
| -560,205,000 | |
| -636,924,000 | |
| -583,641,000 | |
| -524,774,000 | |
| -426,723,000 | |
| -350,859,000 | |
| -348,349,000 | |
| -330,806,000 | |
| -307,631,000 | |
| -272,417,000 | |
| -244,446,000 | |
| -236,048,000 | |
| -227,666,000 | |
| -236,117,000 | |
| -223,446,000 | |
| -199,255,000 | |
| -175,123,000 | |
| -136,318,000 | |
| -114,161,000 | |
| -93,085,000 | |
| -81,205,000 |